CLADRIBINE TABLETS (CT) VERSUS OTHER DISEASE-MODIFYING THERAPIES IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) - COST-EFFECTIVENESS ANALYSIS.

被引：0
|
作者：
Zieiba, P. [1 ]
Pawlik, D. [2 ]
Wieczorek, J. [2 ]
Wojcik, R. [2 ]
Kaczor, M. P. [3 ]
机构：
[1] Merck Sp Zoo, Warsaw, Poland
[2] Aestimo Sc, Krakow, MA, Poland
[3] Jagiellonian Univ Med Coll, Krakow, Poland
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND51
引用
收藏
页码：S632 / S632
页数：1
相关论文
共 50 条
  • [21] Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis
    Tafazzoli, Ali
    Chavan, Ameya
    Harty, Gerard
    Moller, Jorgen
    Wong, Schiffon L.
    [J]. ADVANCES IN THERAPY, 2020, 37 (09) : 3791 - 3806
  • [22] Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis
    Ali Tafazzoli
    Ameya Chavan
    Gerard Harty
    Jorgen Moller
    Schiffon L. Wong
    [J]. Advances in Therapy, 2020, 37 : 3791 - 3806
  • [23] Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
    Ginestal, Ricardo
    Rubio-Terres, Carlos
    Moran, Olga Duran
    Rubio-Rodriguez, Dario
    De Los Santos, Heidi
    Ordonez, Cristina
    Sanchez-Magro, Isabel
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (02)
  • [24] COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Ginestal, R.
    Duran, O.
    Rubio Terres, C.
    Rubio-Rodriguez, D.
    De Los Santos, H.
    Ordonez, C.
    Sanchez, I
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S82 - S82
  • [25] Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis
    Lucchetta, Rosa C.
    Tonin, Fernanda S.
    Borba, Helena H. L.
    Leonart, Leticia P.
    Ferreira, Vinicius L.
    Bonetti, Aline F.
    Riveros, Bruno S.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    [J]. CNS DRUGS, 2018, 32 (09) : 813 - 826
  • [26] COST-CONSEQUENCE OF CLADRIBINE TABLETS FOR THE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK
    Miller, B.
    Russel-Szymczyk, M.
    Jensen, I. S.
    Shah, A.
    Alexopoulos, S. T.
    Herbert, A.
    McLean, T.
    Tundia, N.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S180 - S180
  • [27] Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
    AlRuthia, Yazed
    Balkhi, Bander
    Alkhalifah, Sahar Abdullah
    Aljarallah, Salman
    Almutairi, Lama
    Alanazi, Miteb
    Alajlan, Abdulmalik
    Aldhafiri, Suliman M.
    Alkhawajah, Nuha M.
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (24)
  • [28] Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis
    Siddiqui, Mohd Kashif
    Khurana, Inderpreet Singh
    Budhia, Sangeeta
    Hettle, Robert
    Harty, Gerard
    Wong, Schiffon L.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (08) : 1361 - 1371
  • [29] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Timothy Spelman
    William L. Herring
    Yuanhui Zhang
    Michael Tempest
    Isobel Pearson
    Ulrich Freudensprung
    Carlos Acosta
    Thibaut Dort
    Robert Hyde
    Eva Havrdova
    Dana Horakova
    Maria Trojano
    Giovanna De Luca
    Alessandra Lugaresi
    Guillermo Izquierdo
    Pierre Grammond
    Pierre Duquette
    Raed Alroughani
    Eugenio Pucci
    Franco Granella
    Jeannette Lechner-Scott
    Patrizia Sola
    Diana Ferraro
    Francois Grand’Maison
    Murat Terzi
    Csilla Rozsa
    Cavit Boz
    Raymond Hupperts
    Vincent Van Pesch
    Celia Oreja-Guevara
    Anneke van der Walt
    Vilija G. Jokubaitis
    Tomas Kalincik
    Helmut Butzkueven
    [J]. PharmacoEconomics, 2022, 40 : 323 - 339
  • [30] THE IMPACT OF MODELLING SUBSEQUENT TREATMENT ON ESTIMATES OF COST-EFFECTIVENESS: AN ANALYSIS OF DISEASE-MODIFYING TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED KINGDOM
    Phelps, H.
    Treharne, C.
    Ramirez Guevara, G.
    Bertranou, E.
    [J]. VALUE IN HEALTH, 2018, 21 : S341 - S341
12345